Table of Contents
India’s drug regulator has flagged a batch of the widely used Abhayrab rabies vaccine after laboratory testing found that the sample failed to meet required potency standards. The development has triggered an investigation into whether the batch may be substandard or potentially spurious.
According to a government document reviewed by Reuters, batch KE25012 was found to have a potency problem during testing at the Central Drugs Laboratory in Kasauli. The laboratory also identified discrepancies involving labelling, QR codes and packaging when compared with a reference sample.
Key Health Headlines
- Rabies vaccine batch flagged: Regulators identified concerns involving Abhayrab batch KE25012.
- Potency test failure: The tested sample did not meet the required potency standard.
- Packaging concerns: Differences were identified in labelling, QR codes and packaging.
- Investigation underway: Authorities are examining the matter under India’s Drugs and Cosmetics Act.
- Second concern: This is the second counterfeit-related concern involving Abhayrab in less than two years.
Why Rabies Vaccines Matter
Rabies is a serious viral disease that is almost always fatal once clinical symptoms develop. Timely post-exposure treatment following an animal bite is therefore extremely important.
Abhayrab is a widely used rabies vaccine in India and has reportedly supplied more than 210 million doses in India and more than 40 other countries. India also continues to face a significant rabies burden, making reliable access to safe and effective vaccines an important public-health priority.
What the Investigation Means
The flagged batch does not mean that every Abhayrab dose is unsafe. The regulatory concern relates specifically to the identified batch, while authorities investigate its distribution and authenticity.
The laboratory reportedly found that the sample passed tests for sterility, moisture and identity, but the potency result and packaging discrepancies prompted additional scrutiny. Authorities are expected to determine the extent of distribution and whether any affected doses reached other markets.
What People Should Do
Anyone who has recently received a rabies vaccination should not panic or stop treatment without medical advice. People who have been exposed to a potentially rabid animal should seek medical attention promptly and follow the treatment schedule recommended by a healthcare professional.
The incident also highlights the importance of purchasing medicines and vaccines through authorised healthcare channels and checking packaging carefully.
Web Story Highlights
Rabies vaccine batch under regulatory investigation.
Laboratory testing found a potency issue.
Packaging and labelling discrepancies also reported.
Authorities are investigating the batch under drug laws.
Public health officials continue to focus on vaccine safety.
The investigation is expected to provide more clarity about the affected batch and its distribution. Until then, patients should rely on qualified medical professionals and official health authorities for guidance.
